文献速递关节外科

分期双侧全髋置换中第一髋还是第二髋更接近单侧手术?瑞典髋关节登记研究

Are the First or the Second Hips of Staged Bilateral THAs More Similar to Unilateral Procedures? A Study from the Swedish Hip Arthroplasty Register.
PubMed 文献 · Clin Orthop Relat Res · 2020-01-01

基于瑞典髋关节登记1999-2015年68,357例骨关节炎THA,比较单侧与分期双侧第一髋/第二髋在年龄、合并症、再手术及生存上的相似性。第二髋在年龄、合并症比例和5年再手术率上均与单侧THA无差异,第一髋则更年轻、合并症更少、再手术率更低。作者建议流行病学研究分析第二髋而非第一髋。

要点

  • 第二髋在年龄、合并症和再手术风险上与单侧THA更相似。
  • 第一髋患者更年轻、合并症更少、5年再手术率更低。
  • 建议流行病学研究分析第二髋而非第一髋。

核心结论

  • 分期双侧THA中第二髋在年龄、合并症和再手术风险上比第一髋更接近单侧THA。
  • 建议流行病学研究分析第二髋而非第一髋。

研究设计与样本

  • 瑞典髋关节登记1999-2015年骨关节炎THA共68,357例(63,613例患者),排除一期双侧。
  • 第一髋14,780例(1999-2004),单侧28,542例(2004-2008),第二髋25,035例(2008-2015)。
  • 采用t检验、bootstrap 95%CI、Kaplan-Meier对数秩检验及相对5年生存分析。

主要发现

  • 单侧THA年龄70±10岁,第一髋66±9岁(均差4,p<.001),第二髋70±9岁(均差0,p=0.74)。
  • 单侧合并症比例20%(95%CI 19.8-20.7),第二髋20%(19.7-20.6)无差异,第一髋15%(14.5-15.4)更低。
  • 5年再手术率单侧与第二髋均为3%(95%CI 2.8-3.2),第一髋2%(95%CI 1.8-2.3)。
  • 相对5年生存:单侧105%(104.9-105.9),第二髋107%(106.3-107.4),第一髋109%(108.8-109.5)。

关键数值与推荐

  • 合并症以Charlson指数>0定义,比较前减去年度趋势以避免时期混杂。
  • 再手术风险以Kaplan-Meier曲线对数秩检验及5年再手术率配对95%CI比较。
  • 相对5年生存以同年龄、性别、出生年份的瑞典普通人群为参照。

临床怎么用

  • 流行病学研究分期双侧THA时应优先分析第二髋以更好代表单侧THA。
  • 解读登记数据时需注意第一髋与单侧THA在年龄和合并症上的差异。

局限性

  • 观察性登记数据,不同纳入时期引入潜在时期混杂,合并症和生存存在时间趋势。
  • 仅第一髋未做第二髋者被归为单侧,生存曲线排序存在设计上的永恒时间偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bilateral THAs performed in the same patient should not be considered independent observations, neither biologically nor statistically. As a result, when surgical results are reviewed, it is common to analyze only the first of the two hips, assuming that the first, and not the second hip of a staged bilateral THA, better resembles unilateral THAs. This assumption has not been empirically justified.Question/purposes (1) In patients with staged bilateral THA, is the first or second hip more similar to a unilateral THA in terms of age at surgery, presence of any preoperative Charlson comorbidity, and risk of postoperative reoperation? (2) Should the date of a first or second hip surgery of a staged bilateral THA be used as a starting point for patient survival to better resemble patients with unilateral THA? METHODS: We identified 68,357 THAs due to osteoarthritis in 63,613 patients from the Swedish Hip Arthroplasty Register (SHAR) in 1999-2015. Of those THAs, 14,780 concerned the first hip of a staged bilateral procedure performed between 1999 and 2004; 28,542 were unilaterals from 2004 to 2008, and 25,035 concerned the second hip of a staged bilateral procedure performed 2008 to 2015. We excluded patients who underwent one-stage bilateral THAs. We used different inclusion periods to distinguish unilateral procedures from the first and second hips from staged bilateral procedures because sufficiently long set-up and follow-up periods were needed before and after each period to identify possible contralateral THAs. This introduced potential period confounding, meaning that possible group differences might not be distinguished from unrelated outcome differences over time. We investigated if such time trends existed. It did not for age and reoperation rates, but it did for comorbidity and patient survival. Our primary study endpoint was whether patients with unilateral THAs were more similar to patients with a first hip of a staged bilateral THA, or to patients with their second hip operated. We used Student's t-test to compare mean age at surgery. The proportion of patients with at least one presurgery Charlson comorbidity were compared by 95% bootstrap confidence intervals, after subtracting the yearly time-trend to avoid period confounding. Postoperative risks of reoperation were compared by log-rank tests of Kaplan-Meier curves and by comparing 5-year reoperation rates by pair-wise 95% CIs. Our secondary study endpoint was to compare patient survival for patients with a unilateral THA, a first hip of a staged bilateral THA, or a second hip of a staged bilateral THA. We evaluated this by relative 5-year survival, comparing patients of each group with the general Swedish population of the same age, sex, and year of birth. This way, possible survival differences would be less likely explained by period confounding. RESULTS: Patients undergoing unilateral THA were older than those undergoing a first hip of a staged bilateral THA (70 ± 10 versus 66 ± 9 years, mean difference of 4; p < .001), but they were not different from patients undergoing the second hip of a staged bilateral THA (70 ± 9 years, mean difference of 0; p = 0.74). The period-adjusted proportion of patients with unilateral THA and presurgery comorbidity (Charlson index > 0) was 20% (95% CI: 19.8-20.7). This was no different from patients with a second hip from a staged bilateral THA (20%; 19.7-20.6), but higher compared to patients with a first hip of a staged bilateral THA (15%; 14.5-15.4). For reoperation rates, the log-rank tests showed no difference between unilateral THAs and the second hips of staged bilateral THAs ((Equation is included in full-text article.)). Such difference was found for unilaterals compared with the first hips of staged bilateral THAs ((Equation is included in full-text article.)). The Kaplan-Meier estimate of reoperation rates at 5 years after surgery were also no different for the unilateral THAs compared with the second hips of staged bilateral THAs (3% [95% CI 2.8 to 3.2] for both groups). It was lower (2% [95% CI 1.8 to 2.3]) for a first hip of a staged bilateral THA. For the secondary outcome, the relative 5-year survival differed for all groups. It was 105% (95% CI 104.9 to 105.9) for patients with unilateral THA, 107% (95% CI 106.3 to 107.4) for patients with a second hip from a staged bilateral THA and 109% (95% CI 108.8 to 109.5) for patients with a first hip of a staged bilateral THA. Patients with only a first hip of a planned staged bilateral THA who did not survive long enough to undergo their second THA were classified as unilaterals. The rank-order of survival curves are therefore by design ("immortal time bias"). We conclude, however, that survival for patients with unilateral THA more closely resembles the survival of patients with a second hip of a staged bilateral THA, compared with the first. CONCLUSIONS: Our findings, which are based on observational register data, challenge the common practice in epidemiologic studies of analyzing only the first hip of a staged bilateral THA. We recommend analyzing the second THA in a patient who has undergone staged bilateral THA rather than the first because the second procedure better resembles unilateral THA. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Bülow E, Nemes S, Rolfson O, et al. Are the First or the Second Hips of Staged Bilateral THAs More Similar to Unilateral Procedures? A Study from the Swedish Hip Arthroplasty Register. Clin Orthop Relat Res. 2020. PMID: 32168059. doi:10.1097/CORR.0000000000001210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。